Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSI-301 vs Aflibercept in Treatment-Naïve DME
NCT04611152Phase 3Terminated
- Sponsor
- Kodiak Sciences
- Start
- Sep 2020
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of tarcocimab tedromer in diabetic macular edema (DME) (2 arms), sponsored by Kodiak Sciences. Primary endpoint: Mean Change in Best Corrected Visual Acuity at 64 weeks. Started Sep 2020; status: terminated.
02
Drugs
tarcocimab tedromer
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04611152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611152.